Clinical Trials Directory
We are doing this study to compare the outcomes of 2 treatments for women with stress urinary incontinence (SUI): transurethral bulking agent (TBA) and single-incision sling (SIS). Both treatments are FDA-approved and can help improve SUI symptoms, but they have not been directly compared to each other to see which treatment is better for certain patients and under what circumstances. We hope this study can help women and their doctors find out which option is most likely to have the best results. Current evidence suggests that TBA and SIS are less effective than a traditional full-length mid-urethral sling procedure, but both options are less invasive and less likely to cause complications afterward.
We are doing this study to find out whether certain immunotherapy drug combinations with and without chemotherapy given before and after surgery for mesothelioma can help prevent the tumor from coming back. The two immunotherapy drugs, durvalumab and tremelimumab, are called immune checkpoint inhibitors and are used to activate the immune system against cancer. Immune checkpoint inhibitors are now approved for mesothelioma for patients who cannot undergo surgery, but they are not approved prior to surgery. The chemotherapy drugs (cisplatin or carboplatin and pemetrexed) are standard options for the treatment of mesothelioma.
We are doing this study to find out if an investigational drug called TP-3654 (the study drug) is a safe and effective treatment for myelofibrosis. The study drug will be tested at different doses to find out what effects, if any, it has on myelofibrosis.
Participants will complete various surveys about their health and experience with their new bowel program.
We are doing this study to find out if an experimental drug called BGB-43395 (the study drug) is a safe and effective option for people with for breast cancer and other advanced solid tumors. We want to know how the study drug works on its own and in combination with other cancer drugs.
We are doing this study to find the most safe and effective long-term dose of an experimental drug called zanubrutinib (the study drug) when it is given alone or in combination with other cancer drugs. We want to know how well this study drug works in people with B-cell cancers who are currently participating or previously participated in a BeiGene-sponsored study.
We are doing this study to monitor the health of the cornea in participants with neovascular age-related macular degeneration (nAMD), also know as wet AMD, who receive an eye implant that continuously delivers the drug ranibizumab into the back of the eye.
The study has 4 parts: screening, taking the study drug, stopping the drug, and follow-up. You’ll get tests like blood work, heart checks, and scans. You’ll be randomly given one of two medicines: BGB-16673 or Pirtobrutinib, both taken once a day. After stopping the medicine, you’ll return for a check-up in about a month. If your cancer hasn’t gotten worse, you’ll visit every 6 months. If it has, the study team will check on you by phone or email. The whole study may last about 3 years with around 13 visits.